• 南方医科大学南方医院放疗科研究员、副主任医师、博士、博士研究生导师、博士后合作导师、食管癌亚专科组长、日本德岛大学博士，金泽大学博士后

• 广东省胸部疾病学会食管疾病专委会副主委

• 广东省医学会放射肿瘤学分会常务委员

• 广东省肝脏病学会放射肿瘤专业委员会常务委员

• 广东省医学会胸部肿瘤学组组员

• 广东省医学会肿瘤学分会青年委员会委员

• 广东省抗癌协会食管癌专业委员会委员

• 广州市医师协会放射肿瘤学分会副主委

• 广东省杰出青年医学人才

• 广州实力中青年医师

• 羊城好医生

胸部肿瘤放疗及临床综合治疗、免疫及靶向治疗的靶点开发、作用机制及耐药后治疗；食管癌精准治疗临床研究；

2000年获第四军医大学学士学位，2003年至2011年在日本德岛大学和金泽大学完成博士课程及博士后研究，获得德岛大学医学博士学位。广东省杰出青年医学人才，广州市实力中青年医师，羊城好医生。现任广东省医学会肿瘤学会青年委员、胸部肿瘤学组委员、Internatioanl Journal of Cancer, Oncotarget等国际学术杂志审稿人、国家自然科学基金及广东省自然科学基金评审专家。临床专业方向为食管肿瘤的精确放疗及综合处理。科研方向为肿瘤靶向治疗与免疫治疗，以及放射增敏及防护分子机制的研究。在Cancer Res, Clin Cancer Res等国际权威SCI杂志发表论文三十余篇，近年来陆续发表多篇高质量文章（IF大于10，Nature communication, Molecular cancer)，总影响因子超过200分，最高单篇引用超过400次。以排名第一获得包括日本癌转移学会年度最佳研究奖励赏、日本三德会年度最佳研究奖励等多个奖项。主持完成日本国家级科研基金1项，日中医学会基金1项、国家自然科学基金项目4项，以及广东省高校人才引进专项基金、广东省自然科学基金等多项课题。牵头或作为分中心负责人开展多项全国/全球多中心临床研究。

• 发表SCI论文39篇，最高单篇他引>400，

  代表性论著（#第一作者，*通讯作者）：
• Wang R#, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W*, Suzuki T, Yano S*. Transient IGF-1R Inhibition Combined with Osimertinib Eradicates AXL-low Expressing EGFR Mutated Lung Cancer.  Nature Communications. 2020 Sep 14; 11(1):4607.IF:12.121
• Shunli Peng#, Rong Wang#, Xiaojuan Zhang, Yueyun Ma, Longhui Zhong, Ke Li, Nishiyama Akihiro, Sachiko Arai, Seiji Yano*, Wei Wang*. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019 Nov 20;18(1):165. IF:15.302
• Wang W#, Li Q, Tkeuchi S, Yamada T, Koizumi H, Nkamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S*. Met kinase Inhibitor E7050 Reverse Three Different Mechanisms of Hepatocyte Growth Factor-induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clin Cancer Res. 2012 Mar 15;18(6):1663-71.   IF: 9.619
• Wang W#, Li Q #, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S*. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Clin Cancer Res. 2009 Nov 1;15(21):6630-8.     IF: 9.619
• Yano S#, Wang W#, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S*. HGF induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. Cancer Res. 2008 Nov 15;68(22):9479-87.     IF:8.378
• Donev IS#, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S*. Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. Clin Cancer Res. 2011 Apr 15;17(8):2260-9. IF: 9.619
• Yamada T#, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S*. Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer. Clin Cancer Res. 2010 Jan 1;16(1):174-83. IF: 9.619
• Ikuta K#, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S*. E7080, a Multi-tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles. Clin Cancer Res. 2009 Dec 1;15(23):7229-37.   IF: 9.619
• Li Q#, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S*. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 2007 Oct 1;13(19):5918-25.   IF: 9.619
•  
•  
• 主要论著有：
• Li W#, Wang W*.Decoding the genetic links between serum lipidomic profile, amino acid biomarkers, and programmed cell death protein-1/programmed cell death-ligand-1.Cancer Immunol Immunother. 2023 Oct;72(10):3395-3399. IF=5.8
• Li W#, Wang W*. Insights into risk factors for basal cell carcinoma: a Mendelian randomization study. Clin Exp Dermatol. 2023 Jun 5;48(6):676-680. IF=4.1
• Li W#, Wang R, Wang W*. Exploring the causality and pathogenesis of systemic lupus erythematosus in breast cancer based on Mendelian randomization and transcriptome data analyses.  Front Immunol. 2023 Jan 16;13:1029884. IF=7.3
• Li W#, Huang M, Wang R, Wang W*. Impact of genetically predicted atrial fibrillation on cancer risks: A large cardio-oncology Mendelian randomization study using UK biobank.Front Cardiovasc Med. 2023 Jan 5;9:974402. IF=3.6
• Yueyun Ma #, Wenjie Li #, Shiyu Chen #, Shuimiao Lin, Sijie Ding, Xiaomei Zhou, Tongxin Liu, Rong Wang, Wei Wang*. Characteristics and response to next-generation sequencing-guided therapy in locally advanced or metastatic esophageal cancer. Int J Cancer
  . 2023 Feb 1;152(3):436-446. IF=6.4
• Rong Wang#, Xiaomei Zhou, Tongxin Liu, Shuimiao Lin, Yanxia Wang, Xiaogang Deng, Wei Wang*. Gross Tumor Volume Predicts Survival and Pathological Complete Response of Locally Advanced Esophageal Cancer After Neoadjuvant Chemoradiotherapy. Front Oncol. 2022 Jun 7;12:898383. IF=4.7
• Luo X# , Peng S# , Ding S, Zeng Q, Wang R, Ma Y, Chen S, Wang Y, Wang W*. Prognostic values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. Cancer Cell Int. 2021 Jan 12;21(1):49. IF=4.175
• Wang R#, Yamada T, Kita K, Taniguchi H, Arai S, Fukuda K, Terashima M, Ishimura A, Nishiyama A, Tanimoto A, Takeuchi S, Ohtsubo K, Yamashita K, Yamano T, Yoshimura A, Takayama K, Kaira K, Taniguchi Y, Atagi S, Uehara H, Hanayama R, Matsumoto I, Han X, Matsumoto K, Wang W*, Suzuki T, Yano S*. Transient IGF-1R Inhibition Combined with Osimertinib Eradicates AXL-low Expressing EGFR Mutated Lung Cancer. 2020 Sep 14; 11(1):4607. Nature Communications. IF:12.121
• Shunli Peng#, Rong Wang#, Xiaojuan Zhang, Yueyun Ma, Longhui Zhong, Ke Li, Nishiyama Akihiro, Sachiko Arai, Seiji Yano*, Wei Wang*. EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression. Mol Cancer. 2019 Nov 20;18(1):165. IF:15.302
• Wang R#, Peng S#, Zhang X, Wu Z, Duan H, Yuan Y, Wang W*. Inhibition of NF-κB improves sensitivity to irradiation and EGFR-TKIs and decreases irradiation-induced lung toxicity. Int J Cancer. 2019 Jan 1;144(1):200-209.    IF: 4.981
• Luo X#, Peng S#, Ding S, Zeng Q, Wang R, Ma Y, Chen S, Wang Y, Wang W*. Prognosis values, ceRNA network, and immune regulation function of SDPR in KRAS-mutant lung cancer. Cancer Cell Int. 2021 Jan 12; 21(1):49.  IF: 4.175
• Longhui Zhong#, Rong Wang#, Yanxia Wang, Shunli Peng, Yueyun Ma, Sijie Ding, Hong Yang, Shiyu Chen, Xiaoqing Luo, Wei Wang*. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia. 2020 Sep;22(9):365-375. IF: 5.696
• SiJie Ding#, Rong Wang#, ShunLi Peng, Xiaoqing Luo, LongHui Zhong, Hong Yang, YueYun Ma, ShiYu Chen, Wei Wang*. Targeted therapies for RET-fusion cancer: Dilemmas and breakthrough. Biomedicine & pharmacotherapy. 2020, 132: 110901. IF: 4.545
• Hong Yang#, Rong Wang, Furen Zeng, Jie Zhao, Shunli Peng, Yueyun Ma, Shiyu Chen, Sijie Ding, Longhui Zhong, Wei Guo, Wei Wang*. Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single-center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database. Oncol Lett. 2020 Oct;20(4):87. IF: 2.311
• Yang H#, Wang R, Peng S, Chen L, Li Q*, Wang W*. Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefiinib, in lung adenocarcinoma cells harboring wild-type EGFR. Oncotarget. 2016 Mar 29;7(13):16273-81. IF:5.168
• Zhang Y#, Zheng L#, Ding Y#, Li Q, Wang R, Liu T, Sun Q, Yang H, Peng S, Wang W*, Chen L*.MiR-20 a Induces Cell Radioresistance by Activating the PTEN/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):1132-40.   IF:6.203
• Liu T#, Sun Q#, Li Q#, Yang H, Zhang Y, Wang R, Lin X, Xiao D, Yuan Y, Chen L*, Wang W*. Dual PI3K/mTOR inhibitors, GSK2126458 and PKI-587, suppress tumor progression and increase radiosensitivity in nasopharyngeal carcinoma. Mol Cancer Ther. 2015 Feb;14(2):429-39     IF:5.579
• Liu T#, Li Q#, Sun Q, Zhang Y, Yang H, Wang R, Chen L*, Wang W*. MET inhibitor PHA-665752 suppresses the hepatocyte growth factor-induced cell proliferation and radioresistance in nasopharyngeal carcinoma cells. Biochem Biophys Res Commun. 2014 Jun 20;449(1):49-54.     IF:2.705
• Wang W#, Li Q, Tkeuchi S, Yamada T, Koizumi H, Nkamura T, Matsumoto K, Mukaida N, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S*. Met kinase Inhibitor E7050 Reverse Three Different Mechanisms of Hepatocyte Growth Factor-induced Tyrosine Kinase Inhibitor Resistance in EGFR Mutant Lung Cancer. Clin Cancer Res. 2012 Mar 15;18(6):1663-71.   IF: 9.619
• Wang W#, Li Q #, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S*. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Clin Cancer Res. 2009 Nov 1;15(21):6630-8.     IF: 9.619
• Li Q#, Wang W#, Yamada T, Matsumto K, Bando Y, Uehara H, Nishioka Y, Sone S, Iwakiri S, Itoi K, Utsugi T, Yasumoto K, Yano S*. Pleural Mesothelioma Instigates Tumor-associated Fibroblasts to Promote Progression via a Malignant Cytokine Network. American Jounal of Pathology. 2011 Sep;179(3):1483-93.     IF:4.89
• Wang W#, Nishioka Y, Ozaki S, Jalili A, Abe S, Kisyuku M, Minakuchi K, Matsumoto T, Sone S*. HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother. 2009 Jun;58(6):967-76.     IF:4.9
• Wang W#, Nishioka Y, Ozaki S, Jalili A, Verma VK, Hanibuchi M, Abe S, Minakuchi K, Matsumoto T, Sone S*. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer. 2009 Jan;63(1):23-31.     IF:4.599
• Yano S#, Wang W#, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S*. HGF induces gefitinib resistance of lung adenocarcinoma cells with EGF receptor mutations. Cancer Res. 2008 Nov 15;68(22):9479-87.     IF:8.378
• 刘倩,王玮*. 浅谈宫颈癌临床治疗新进展. 实用医学杂志. 2018,34(1):5-7.
• 刘倩,孙爱民,王玮*. 固有免疫细胞抗肿瘤免疫治疗的研究进展. 现代肿瘤医学. 2018,26(8):1292-1295
• 李琦,刘同欣,王融,王玮. c-Met 抑制剂对人鼻咽癌细胞株 CNE-1 的生长抑制作用. 实用医学杂志,2015,31(4):536-539.
• Nanjo S#, Arai S, Wang W, Takeuchi S, Yamada T, Hata A, Katakami N, Okada Y, Yano S*. MET Copy Number Gain Is Associated with Gefitinib Resistance in Leptomeningeal Carcinomatosis of EGFR-mutant Lung Cancer. Mol Cancer Ther. 2017 Mar;16(3):506-515.     IF: 5.579
• Sun Q#, Liu T#, Yuan Y*, Guo Z, Xie G, Du S, Lin X, Xu Z, Liu M, Wang W, Yuan Q, Chen L. MiR-200c inhibits autophagy and enhances radiosensitivity in breast cancer cells by targeting UBQLN1. Int J Cancer. 2015 Mar 1;136(5):1003-12.     IF: 7.360
• Li Q#, Wang W, Machino Y, Yamada T, Kita K, Oshima M, Sekido Y, Tsuchiya M, Suzuki Y, Nan-Ya K, Iida S, Nakamura K, Iwakiri S, Itoi K, Yano S*. Therapeutic activity of glycoengineered anti-GM2 antibodies against malignant pleural mesothelioma. Cancer Sci. 2015 Jan;106(1):102-7.     IF:4.751
• Yamada T#, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, Yoshida J, Higashiyama M, Noguchi M, Uehara H, Nishioka Y, Sone S, Yano S*. Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene. 2013 Sep 12;32(37):4427-35.    IF:8.559
  Takeuchi S#, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka 
• Y, Sone S, Nakagawa T, Uenaka T, Yano S*. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 2012 Sep;181(3):1034-43.    IF: 4.89
• Yamada T#, Bando H, Takeuchi S, Kita K, Li Q, Wang W, Akinaga S, Nishioka Y, Sone S, Yano S*. Genetically engineered humanized anti-ganglioside GM2 antibody against multiple organ metastasis produced by GM2-expressing small-cell lung cancer cells. Cancer Sci. 2011 Dec;102(12):2157-63.   IF: 4.751
• Ogino H#, Hanibuchi M, Kakiuchi S, Trung VT, Goto H, Ikuta K, Yamada T, Uehara H, Tsuruoka A, Uenaka T, Wang W, Li Q, Takeuchi S, Yano S, Nishioka Y, Sone S*. E7080, a Multiple Tyrosine Kinase Inhibitor, Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Non-mutated Epidermal Growth Factor Receptor.Mol Cancer Ther. 2011 Jul;10(7):1218-28. IF: 5.579
• Yasumoto K#, Yamada T, Kawashima A, Wang W, Li Q, Shterev DI, Tacheuchi S, Mouri H, Yamashita K, Ohtsubo K, Yano S*. The EGFR ligands Amphiregulin and Heparin-binding EGF-like Growth Factor Promote Peritoneal Carcinomatosis in CXCR4-expressing Gastric Cancer. Clin Cancer Res. 2011 Jun 1;17(11):3619-30.    IF: 9.619
• Yano S#, Wang W, Li Q, Yamada T, Takeuchi S, Matsumoto K, Nishioka Y, Sone S*. HGF-MET in Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer. Current Signal Transduction Therapy. May 2011; 6(2):228-233.  IF:0.5
• Donev IS#, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S*. Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer. Clin Cancer Res. 2011 Apr 15;17(8):2260-9. IF: 9.619
• Yano S#, Li Q, Wang W, Yamada T, Takeuchi S, Nakataki E, Ogino H, Goto H, Nishioka Y, Sone S*. Antiangiogenic therapies for malignant pleural mesothelioma. Front Biosci. 2011 Jan 1;16: 740-8. IF:3.52
• Yamada T#, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S*. Hepatocyte Growth Factor Reduces Susceptibility to an Irreversible Epidermal Growth Factor Receptor Inhibitor in EGFR-T790M Mutant Lung Cancer. Clin Cancer Res. 2010 Jan 1;16(1):174-83. IF: 9.619
• Ikuta K#, Yano S, Trung VT, Hanibuchi M, Goto H, Li Q, Wang W, Yamada T, Ogino H, Kakiuchi S, Uehara H, Sekido Y, Uenaka T, Nishioka Y, Sone S*. E7080, a Multi-tyrosine Kinase Inhibitor, Suppresses the Progression of Malignant Pleural Mesothelioma with Different Proangiogenic Cytokine Production Profiles. Clin Cancer Res. 2009 Dec 1;15(23):7229-37.   IF: 9.619
• Li Q#, Yano S, Ogino H, Wang W, Uehara H, Nishioka Y, Sone S*. The therapeutic efficacy of anti-vascular endothelial growth factor antibody, bevacizumab, and pemetrexed against orthotopically implanted human pleural mesothelioma cells in severe combined immunodeficient mice. Clin Cancer Res. 2007 Oct 1;13(19):5918-25.   IF: 9.619
• Nishioka Y#, Manabe K, Kishi J, Wang W, Inayama M, Azuma M, Sone S*. CXCL9 and 11 in patients with pulmonary sarcoidosis: a role of alveolar macrophages. Clin Exp Immunol. 2007 Aug;149(2):317-26.   IF:3.711
• 林淑慧,谢国柱,张静芳,蔡小慧,姚奇伟,孙权权,王玮,袁亚维. 坎地沙坦对人乳腺癌细胞株MCF-7生长抑制作用的研究. 实用医学杂志,2014,30(4):511-514.